EDX Medical Group
Chris Evans is a seasoned professional in the healthcare sector, currently serving as the Founder and Director of EDX Medical since March 2022. Prior to this role, Chris held the position of Chairman at Excalibur Healthcare Services Ltd from January 2020 to July 2023, demonstrating strong leadership and commitment to advancing healthcare initiatives.
This person is not in any teams
EDX Medical Group
EDX Medical Group PLC develops innovative digital diagnostic products and services, enabling personalised treatment for cancer, heart disease and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX). EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally. EDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and 100%-owned subsidiary companies, Hutano Diagnostics Limited in Oxford, UK, and Torax Biosciences Ltd in Ireland. EDX Medical provides testing and genomic sequencing services, undertakes quality assurance, conducts research & development (R&D) and has established expertise in the design, development, validation and sourcing of diagnostic testing solutions to ISO 13485. Key laboratory tests performed by the Company have been accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS).